Oklahoma State University–Tulsa, located in Tulsa, Oklahoma, United States, is the newest institution of the Oklahoma State University System. It was previously the University Center at Tulsa until it became OSU-Tulsa on January 1, 1999.

During the past decade, Oklahoma State University conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 1 clinical trials were completed, i.e. on average, 50% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 1 clinical trials were completed. i.e. 100% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Oklahoma State University" #1 sponsor was "La Jolla Pharmaceutical Company" with 1 trials, followed by "Northwestern University" with 1 trials sponsored, "Pfizer" with 1 trials sponsored, "Spiration, Inc." with 1 trials sponsored and "University of Nebraska Lincoln" with 1 trials sponsored. Other sponsors include -5 different institutions and companies that sponsored additional 5 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Oklahoma State University" #1 collaborator was "Department of Health and Human Services" with 1 trials as a collaborator and "National Institutes of Health (NIH)" with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 2 trials.

According to Clinical.Site data, the most researched conditions in "Oklahoma State University" are "Autoimmune Diseases" (1 trials), "COPD" (1 trials), "Children" (1 trials), "Cystitis, Interstitial" (1 trials) and "Emphysema" (1 trials). Many other conditions were trialed in "Oklahoma State University" in a lesser frequency.

Most popular intervention types in "Oklahoma State University" are "Behavioral" (2 trials), "Biological" (1 trials), "Device" (1 trials), "Drug" (1 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Abetimus sodium (LJP 394)" (1 trials), "CareerAdvance®" (1 trials), "IBV® Valve System" (1 trials), "Placebo" (1 trials) and "Safety Education Program" (1 trials). Other intervention names were less common.

The vast majority of trials in "Oklahoma State University" are 5 trials for "All" genders.

Currently, there are NaN active trials in "Oklahoma State University". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 4 completed trials in Oklahoma State University, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Oklahoma State University, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 1 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 3 trials that are defined as “Not Applicable".